Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GENERAL ELECTRIC COGE · Entity 2813 | Director | April 02, 2018 | April 02, 2018 |
| Quanterix CorpQTRX · Entity 6649 | Director | January 11, 2021 | June 08, 2021 |
| Quantum-Si IncQSI · Entity 6440 | Director | May 11, 2022 | May 13, 2022 |
| THERMO FISHER SCIENTIFIC INC.TMO · Entity 2836 | Director · Chief Executive Officer | August 17, 2009 | August 18, 2009 |
| Telesis Bio Inc.TBIO · Entity 15606 | 10% owner | June 05, 2023 | June 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GENERAL ELECTRIC CO
Report date April 02, 2018 · Filed April 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Fee Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 52,242 |
Reported balance
After 2018-04-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-04-02 · Grant · Acquired 5,512 · Balance 52,242 F1: Acquired at a price of $14.06 per unit pursuant to the terms of the 2007 Long-Term Incentive Plan. Payable beginning one year after termination of service as a director. F2: Each unit of phantom stock is the economic equivalent of one share of common stock. F3: Payable beginning one year after termination of service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquired at a price of $14.06 per unit pursuant to the terms of the 2007 Long-Term Incentive Plan. Payable beginning one year after termination of service as a director.
F2: Each unit of phantom stock is the economic equivalent of one share of common stock.
F3: Payable beginning one year after termination of service as a director.
Quanterix Corp
Report date January 11, 2021 · Filed June 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,270 |
Last balance in matching sequence
After 2021-06-07 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 1 · 2021-06-04 · Exercise / conversion · Acquired 1,951 · Balance 11,031 F1: Includes 2,270 restricted stock units. Row 2 · 2021-06-04 · Exercise / conversion · Acquired 3,168 · Balance 14,199 F1: Includes 2,270 restricted stock units. Row 3 · 2021-06-04 · Sale · Disposed 7,610 · Balance 6,589 F2: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F3: This transaction was executed in multiple trades at prices ranging from $55.00 to $55.11. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1: Includes 2,270 restricted stock units. Row 4 · 2021-06-07 · Exercise / conversion · Acquired 4,732 · Balance 11,321 F1: Includes 2,270 restricted stock units. Row 5 · 2021-06-07 · Sale · Disposed 4,360 · Balance 6,961 F2: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F4: This transaction was executed in multiple trades at prices ranging from $55.17 to $56.16. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1: Includes 2,270 restricted stock units. Row 6 · 2021-06-07 · Sale · Disposed 4,691 · Balance 2,270 F2: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F5: This transaction was executed in multiple trades at prices ranging from $56.17 to $56.41. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1: Includes 2,270 restricted stock units. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.16 · Expires 2027-03-31 | Direct | 0 |
Reported balance
After 2021-06-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-06-04 · Exercise / conversion · Disposed 1,951 · Balance 0 F6: The option vests as to 25% of the shares on March 13, 2018 and vests as to an additional 2.083% of the shares per month thereafter until February 28, 2021. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.12 · Expires 2030-01-02 | Direct | 4,732 |
Reported balance
After 2021-06-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-06-04 · Exercise / conversion · Disposed 3,168 · Balance 4,732 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.12 · Expires 2030-01-02 | Direct | 0 |
Reported balance
After 2021-06-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-06-07 · Exercise / conversion · Disposed 4,732 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 2,270 restricted stock units.
F2: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021.
F3: This transaction was executed in multiple trades at prices ranging from $55.00 to $55.11. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $55.17 to $56.16. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $56.17 to $56.41. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: The option vests as to 25% of the shares on March 13, 2018 and vests as to an additional 2.083% of the shares per month thereafter until February 28, 2021.
Quantum-Si Inc
Report date May 11, 2022 · Filed May 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.06 · Expires 2032-05-11 | Direct | 59,880 |
Reported balance
After 2022-05-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-11 · Grant · Acquired 59,880 · Balance 59,880 F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Dr. Dekkers' continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Dr. Dekkers' continued service through the applicable vesting date.
THERMO FISHER SCIENTIFIC INC.
Report date August 17, 2009 · Filed August 18, 2009
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,554 |
Ending reported balance
After 2009-08-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2009-08-17 · Grant · Acquired 23,600 · Balance 47,481 F1: Represents shares awarded as performance restricted stock awards on November 9, 2006, for which the performance criteria have been satisfied. Row 2 · 2009-08-17 · Tax withholding · Disposed 4,927 · Balance 42,554 |
| Common StockSEC Table I · non-derivative | IndirectBy GRAT | 60,260 |
Reported balance
Holding disclosure · report date 2009-08-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 60,260 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares awarded as performance restricted stock awards on November 9, 2006, for which the performance criteria have been satisfied.
Telesis Bio Inc.
Report date June 05, 2023 · Filed June 08, 2023
Jointly reported with Novalis LifeSciences Investments II GP, LLC, Novalis LifeSciences Investments II, L.P., MEISTER PAUL M
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.36 | IndirectSee footnotes | Not disclosed |
Reported balance
Holding disclosure · report date 2023-06-05 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Each share of Redeemable Convertible Preferred Stock has a stated value of $100 (the "Stated Value") and accrues dividends daily at an initial rate of 8.0% per annum. The Stated Value, as adjusted to give effect to such dividends, is referred to as the "Accrued Value." Each share of Redeemable Convertible Preferred Stock is convertible, at the option of the holder or, upon the occurrence of certain events, at the option of the Issuer, into a number of shares of the Issuer's Common Stock determined by dividing the Accrued Value by the conversion price. The Redeemable Convertible Preferred Stock is not convertible to the extent that such conversion would result in the holder of such Redeemable Convertible Preferred Stock, together with its attribution parties, beneficially owning in excess of 19.99% of the Issuer's voting power. F3: Represents securities held directly by Novalis LifeSciences Investments II, L.P. ("Novalis LifeSciences"). Novalis LifeSciences Investments II GP, LLC ("Novalis LifeSciences GP"), whose managers are Marijn Dekkers and Paul Meister, is the general partner of Novalis LifeSciences. As a result, Novalis LifeSciences GP, Mr. Dekkers and Mr. Meister may each be deemed to share voting and dispositive power with respect to the securities held by Novalis LifeSciences. Novalis LifeSciences GP, Mr. Dekkers and Mr. Meister each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F4: Mr. Meister is a director of the issuer. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.60 · Expires 2030-06-05 | IndirectSee footnotes | Not disclosed |
Reported balance
Holding disclosure · report date 2023-06-05 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The warrants are not exercisable to the extent that such exercise would result in the holder of such warrant, together with its attribution parties, beneficially owning in excess of 19.99% of the Issuer's voting power. F3: Represents securities held directly by Novalis LifeSciences Investments II, L.P. ("Novalis LifeSciences"). Novalis LifeSciences Investments II GP, LLC ("Novalis LifeSciences GP"), whose managers are Marijn Dekkers and Paul Meister, is the general partner of Novalis LifeSciences. As a result, Novalis LifeSciences GP, Mr. Dekkers and Mr. Meister may each be deemed to share voting and dispositive power with respect to the securities held by Novalis LifeSciences. Novalis LifeSciences GP, Mr. Dekkers and Mr. Meister each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F4: Mr. Meister is a director of the issuer. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.60 · Expires 2025-06-05 | IndirectSee footnotes | Not disclosed |
Reported balance
Holding disclosure · report date 2023-06-05 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: The warrants are not exercisable to the extent that such exercise would result in the holder of such warrant, together with its attribution parties, beneficially owning in excess of 19.99% of the Issuer's voting power. F3: Represents securities held directly by Novalis LifeSciences Investments II, L.P. ("Novalis LifeSciences"). Novalis LifeSciences Investments II GP, LLC ("Novalis LifeSciences GP"), whose managers are Marijn Dekkers and Paul Meister, is the general partner of Novalis LifeSciences. As a result, Novalis LifeSciences GP, Mr. Dekkers and Mr. Meister may each be deemed to share voting and dispositive power with respect to the securities held by Novalis LifeSciences. Novalis LifeSciences GP, Mr. Dekkers and Mr. Meister each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F4: Mr. Meister is a director of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Redeemable Convertible Preferred Stock has a stated value of $100 (the "Stated Value") and accrues dividends daily at an initial rate of 8.0% per annum. The Stated Value, as adjusted to give effect to such dividends, is referred to as the "Accrued Value." Each share of Redeemable Convertible Preferred Stock is convertible, at the option of the holder or, upon the occurrence of certain events, at the option of the Issuer, into a number of shares of the Issuer's Common Stock determined by dividing the Accrued Value by the conversion price. The Redeemable Convertible Preferred Stock is not convertible to the extent that such conversion would result in the holder of such Redeemable Convertible Preferred Stock, together with its attribution parties, beneficially owning in excess of 19.99% of the Issuer's voting power.
F2: The warrants are not exercisable to the extent that such exercise would result in the holder of such warrant, together with its attribution parties, beneficially owning in excess of 19.99% of the Issuer's voting power.
F3: Represents securities held directly by Novalis LifeSciences Investments II, L.P. ("Novalis LifeSciences"). Novalis LifeSciences Investments II GP, LLC ("Novalis LifeSciences GP"), whose managers are Marijn Dekkers and Paul Meister, is the general partner of Novalis LifeSciences. As a result, Novalis LifeSciences GP, Mr. Dekkers and Mr. Meister may each be deemed to share voting and dispositive power with respect to the securities held by Novalis LifeSciences. Novalis LifeSciences GP, Mr. Dekkers and Mr. Meister each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
F4: Mr. Meister is a director of the issuer.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cerevel Therapeutics Holdings, Inc.
Report date August 01, 2024 · Filed August 05, 2024
Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-08-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-08-01 · Disposition to issuer · Disposed 31,822 · Balance 10,461 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Row 2 · 2024-08-01 · Disposition to issuer · Disposed 10,461 · Balance 0 F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-08-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-08-01 · Disposition to issuer · Disposed 402,326 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. F3: Represents shares held by Novalis LifeSciences Investments I, L.P. ("Novalis LifeSciences"). The Reporting Person, the Manager of the general partner of Novalis LifeSciences, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-08-01 · Disposition to issuer · Disposed 95,242 · Balance 0 F4: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.
F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
F3: Represents shares held by Novalis LifeSciences Investments I, L.P. ("Novalis LifeSciences"). The Reporting Person, the Manager of the general partner of Novalis LifeSciences, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F4: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
Ginkgo Bioworks Holdings, Inc.
Report date June 12, 2024 · Filed June 14, 2024
Section 16 reporting ended · disclosed 2024-06-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 386,480 |
Reported balance
After 2024-06-12 transaction · row 1
1 source rowRow 1 · 2024-06-12 · Exercise / conversion · Acquired 105,263 · Balance 386,480 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-12 · Exercise / conversion · Disposed 105,263 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Novalis LifeSciences Investments I, L.P. | 5,515,364 |
Reported balance
Holding disclosure · report date 2024-06-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,515,364 F2: Includes 464,481 earn-out shares that will vest in substantially equal installments if the Issuer's Class A Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $15.00, $17.50 and $20.00. F3: The Reporting Person is the manager of the general partner of Novalis LifeSciences Investments I, L.P. ("Novalis LifeSciences"), and as such, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: Includes 464,481 earn-out shares that will vest in substantially equal installments if the Issuer's Class A Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $15.00, $17.50 and $20.00.
F3: The Reporting Person is the manager of the general partner of Novalis LifeSciences Investments I, L.P. ("Novalis LifeSciences"), and as such, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences.
F4: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 1,100 | $43.72 | $48,092.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 23 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,992 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 1,100 | $43.73 | $48,103.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 22 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,092 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 1,000 | $43.74 | $43,740.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 21 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,192 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 1,000 | $43.75 | $43,750.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 20 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,192 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 1,200 | $43.76 | $52,512.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 19 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,192 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 1,400 | $43.77 | $61,278.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 18 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,392 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 1,800 | $43.78 | $78,804.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 17 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,792 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 3,900 | $43.79 | $170,781.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 16 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,592 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 14,500 | $43.80 | $635,100.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 15 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,492 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 6,600 | $43.81 | $289,146.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 14 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,992 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 2,400 | $43.82 | $105,168.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 13 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,592 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 1,900 | $43.83 | $83,277.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 12 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,992 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 300 | $43.84 | $13,152.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 11 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,892 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 4,700 | $43.85 | $206,095.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 10 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,192 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 900 | $43.86 | $39,474.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 9 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,892 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 500 | $43.87 | $21,935.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 8 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,792 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 400 | $43.88 | $17,552.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 7 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,292 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 7,500 | $43.90 | $329,250.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 6 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,692 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 900 | $43.91 | $39,519.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 5 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,192 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 100 | $43.92 | $4,392.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 4 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,092 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 500 | $43.93 | $21,965.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 3 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,192 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 2,000 | $43.95 | $87,900.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 2 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,692 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionCommon Stock | 80,000 | $19.50 | $1,560,000.00 |
DisclosureSEC source: 0000097745-06-000241 · dek423.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 1,600 | $43.50 | $69,600.00 |
DisclosureSEC source: 0000097745-06-000242 · dek425.xml · nonDerivative · entry 5 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,692 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 4,600 | $43.51 | $200,146.00 |
DisclosureSEC source: 0000097745-06-000242 · dek425.xml · nonDerivative · entry 4 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,292 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 500 | $43.52 | $21,760.00 |
DisclosureSEC source: 0000097745-06-000242 · dek425.xml · nonDerivative · entry 3 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,892 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 600 | $43.53 | $26,118.00 |
DisclosureSEC source: 0000097745-06-000242 · dek425.xml · nonDerivative · entry 2 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,392 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 20, 2006 Filed Nov 22, 2006 20:59 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 300 | $43.54 | $13,062.00 |
DisclosureSEC source: 0000097745-06-000242 · dek425.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,992 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2006. Read SEC document |
| November 09, 2006 Filed Nov 15, 2006 01:13 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantStock Option (Right to Buy) · Derivative | 549,900 | $0.00 Strike: $43.37 | $0.00 |
DisclosureSEC source: 0000097745-06-000210 · dek347.xml · derivative · entry 2 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,900 Underlying: Common Stock · 549,900 shares Expires 2013-11-09 F1 · derivative.exercise_date: The option vests in five equal annual installments beginning on November 9, 2007. Read SEC document |
| November 09, 2006 Filed Nov 15, 2006 01:13 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 47,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000097745-06-000210 · dek347.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,618 Read SEC document |
| November 09, 2006 Filed Nov 22, 2006 20:59 UTC Amendment | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantStock Option (Right to Buy) · Derivative | 549,900 | $0.00 Strike: $43.37 | $0.00 |
DisclosureSEC source: 0000097745-06-000240 · dek417.xml · derivative · entry 3 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,900 Underlying: Common Stock · 549,900 shares Expires 2013-11-09 F1 · derivative.exercise_date: The option vests in five equal annual installments beginning on November 9, 2007. Read SEC document |
| November 09, 2006 Filed Nov 22, 2006 20:59 UTC Amendment | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 45,926 | $43.37 | $1,991,810.62 |
DisclosureSEC source: 0000097745-06-000240 · dek417.xml · nonDerivative · entry 2 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,692 Read SEC document |
| November 09, 2006 Filed Nov 22, 2006 20:59 UTC Amendment | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 47,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000097745-06-000240 · dek417.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,618 Read SEC document |
| November 09, 2006 Filed Mar 3, 2008 19:33 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionRestricted Stock Units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000097745-08-000049 · dek620.xml · derivative · entry 3 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: 1 for 1 F1 · derivative.exercise_date: The Reporting Person received a restricted stock unit grant on November 21, 2002, which was reported as a derivative security in Table II of a Form 4 filed on November 22, 2002. The grant provided that no common stock was to be delivered with respect to the grant until the termination of the employment of the Reporting Person. The grant also provided for distribution of the shares immediately before a Change in Control. The merger of the Issuer with Fisher Scientific International Inc. on November 9, 2006 constituted a Change in Control of the Issuer; however, the distribution of shares was inadvertently overlooked until the Issuer's discovery of this oversight in 2008, and the shares were delivered to the Reporting Person on February 28, 2008. F1 · derivative.expiration_date: The Reporting Person received a restricted stock unit grant on November 21, 2002, which was reported as a derivative security in Table II of a Form 4 filed on November 22, 2002. The grant provided that no common stock was to be delivered with respect to the grant until the termination of the employment of the Reporting Person. The grant also provided for distribution of the shares immediately before a Change in Control. The merger of the Issuer with Fisher Scientific International Inc. on November 9, 2006 constituted a Change in Control of the Issuer; however, the distribution of shares was inadvertently overlooked until the Issuer's discovery of this oversight in 2008, and the shares were delivered to the Reporting Person on February 28, 2008. Read SEC document |
| November 09, 2006 Filed Mar 3, 2008 19:33 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000097745-08-000049 · dek620.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Reporting Person received a restricted stock unit grant on November 21, 2002, which was reported as a derivative security in Table II of a Form 4 filed on November 22, 2002. The grant provided that no common stock was to be delivered with respect to the grant until the termination of the employment of the Reporting Person. The grant also provided for distribution of the shares immediately before a Change in Control. The merger of the Issuer with Fisher Scientific International Inc. on November 9, 2006 constituted a Change in Control of the Issuer; however, the distribution of shares was inadvertently overlooked until the Issuer's discovery of this oversight in 2008, and the shares were delivered to the Reporting Person on February 28, 2008. Read SEC document |
| February 27, 2006 Filed Mar 1, 2006 22:44 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $34.86 | $0.00 |
DisclosureSEC source: 0000097745-06-000041 · dek317.xml · derivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2013-02-27 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on February 27, 2007. Read SEC document |
| January 07, 2006 Filed Jan 9, 2006 19:56 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000097745-06-000004 · dek303.xml · nonDerivative · entry 2 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,028 Read SEC document |
| January 07, 2006 Filed Jan 9, 2006 19:56 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 1,506 | $30.44 | $45,842.64 |
DisclosureSEC source: 0000097745-06-000004 · dek303.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,028 Read SEC document |
| February 25, 2005 Filed Feb 28, 2005 22:49 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantStock Option (Right to Buy) · Derivative | 438,000 | $0.00 Strike: $27.40 | $0.00 |
DisclosureSEC source: 0000097745-05-000024 · dek256.xml · derivative · entry 2 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,000 Underlying: Common Stock · 438,000 shares Expires 2012-02-25 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on February 25, 2006. Read SEC document |
| February 25, 2005 Filed Feb 28, 2005 22:49 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000097745-05-000024 · dek256.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,534 Read SEC document |
| January 07, 2005 Filed Jan 11, 2005 21:38 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000097745-05-000004 · dek251.xml · nonDerivative · entry 2 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,067 Read SEC document |
| January 07, 2005 Filed Jan 11, 2005 21:38 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 633 | $28.82 | $18,243.06 |
DisclosureSEC source: 0000097745-05-000004 · dek251.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,067 Read SEC document |
| January 07, 2004 Filed Jan 8, 2004 16:32 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000097745-04-000008 · dek198.xml · nonDerivative · entry 1 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,458 Read SEC document |
| July 25, 2003 Filed Jul 28, 2003 22:13 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 4,500 | $22.09 | $99,405.00 |
DisclosureSEC source: 0000097745-03-000122 · dek121.xml · nonDerivative · entry 12 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,458 Read SEC document |
| July 25, 2003 Filed Jul 28, 2003 22:13 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 2,100 | $22.08 | $46,368.00 |
DisclosureSEC source: 0000097745-03-000122 · dek121.xml · nonDerivative · entry 11 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,958 Read SEC document |
| July 25, 2003 Filed Jul 28, 2003 22:13 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 2,100 | $22.07 | $46,347.00 |
DisclosureSEC source: 0000097745-03-000122 · dek121.xml · nonDerivative · entry 10 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,058 Read SEC document |
| July 25, 2003 Filed Jul 28, 2003 22:13 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 5,000 | $22.05 | $110,250.00 |
DisclosureSEC source: 0000097745-03-000122 · dek121.xml · nonDerivative · entry 9 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,158 Read SEC document |
| July 25, 2003 Filed Jul 28, 2003 22:13 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 8,900 | $22.04 | $196,156.00 |
DisclosureSEC source: 0000097745-03-000122 · dek121.xml · nonDerivative · entry 8 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,158 Read SEC document |
| July 25, 2003 Filed Jul 28, 2003 22:13 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 3,916 | $22.03 | $86,269.48 |
DisclosureSEC source: 0000097745-03-000122 · dek121.xml · nonDerivative · entry 7 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,058 Read SEC document |
| July 25, 2003 Filed Jul 28, 2003 22:13 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 100 | $22.02 | $2,202.00 |
DisclosureSEC source: 0000097745-03-000122 · dek121.xml · nonDerivative · entry 6 DEKKERS MARIJN E · CIK 0001216068 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,974 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.